Publication Month: Jun 2022 | Report Code: TIPRE00029411 | No. of Pages: 277 | Category: Pharmaceuticals | Status: Published
Human papillomaviruses (HPV) is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of HPV have been characterized. The increasing prevalence of various cancers caused by HPV is expected to drive the human papillomavirus (HPV) vaccine market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), HPV is the most common sexually transmitted infection in the US. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to HPV infection. CDC also states that about 14 million people are newly infected by the virus every year in the US.
|Market Size Value in||US$ 4,273.84 million in 2022|
|Market Size Value by||US$ 5,730.50 million by 2028|
|Growth rate||CAGR of 5.0% from 2022 to 2028.|
|No. of Pages||277|
|No. of Tables||223|
|No. of Charts & Figures||99|
|Historical data available||Yes|
|Segments covered||Type, Dosage, Application, and Distribution Channel|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The global human papillomavirus (HPV) vaccine market is segmented on the basis of type, dosage, age, distribution channel, and geography. The market, by region, is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the human papillomavirus (HPV) vaccine market, emphasizing on various parameters such as market trends, technological advancements, and market dynamics. It also includes the competitive landscape analysis of leading market players across the globe.
Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is likely to drive the market's growth.
In women, cervical cancer is the fourth most common cancer. As per the World Health Organization (WHO) report estimation, in 2018, an estimated 570,000 women worldwide had cervical cancer, and about 311,000 female deaths were due to cervical cancer. Additionally, the American Society of Clinical Oncology (ASCO) estimated that around 14,100 cases of invasive cervical cancer would be registered in the US alone. Further, as per the report, 'Cervical cancer burden in EU-27,' in 2020, there were 30,447 new cases and 13,437 deaths due to cervical cancer in women.
Further, as per the Centers for Disease Control and Prevention (CDC), in 2018, there were around 43 million HPV infections in the US. The CDC also estimated that about 19,400 women and 12,100 men annually suffer from cancers caused by HPV. Further, as per the National Foundation for Infectious Diseases (NFID), there are around 14 million new HPV infection cases in the US every year. In addition, as per the report, titled 'Human Papillomavirus and Related Diseases Report-Europe,' in 2020, 8,449 women and 4,327 men had anal cancer in Europe.
Such a high incidence of HPV associated infections across the world is likely to favor the overall market growth in the coming years.
Based on dosage, the human papillomavirus (HPV) vaccine market is segmented into 2 dose and 3 dose. In 2022, the 2 dose segment accounts for a larger market share.
On the basis of distribution channel, the global human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment holds the largest share of the market in 2022, and the school-based health centers segment is anticipated to register the highest CAGR in the market during the forecast period.
The COVID-19 pandemic is likely to have longer-term consequences on the HPV vaccine business. Many primary care clinics in the US have continued to operate at a reduced capacity to abide by social distancing measures and adopt stringent cleaning protocols. A reduction in in-person office visits limits opportunities for vaccine providers to discuss and deliver vaccines. Barriers in transportation are likely to harm HPV vaccination; pharma and biotech companies traditionally find it difficult to market vaccines among the masses because of resistance received from parents and the absence of widespread awareness about school entry requirements that support other adolescent vaccines. The available evidence indicates that the COVID-19 pandemic has dramatically disrupted the delivery of HPV vaccines in 2020 and 2021. Early reports by CDC, suggest that ordering and billing dropped by >70% in March 2020. Furthermore, a 25–50% decrease in HPV vaccine orders continued in June 2020, in contrast to other early childhood-vaccine orders that resurged to near pre-pandemic levels. Although the revival of the HPV vaccine market is in progress, available data suggest that a short-term decline in HPV vaccination coverage will be substantial, and the demand for HPV vaccine will grow across North America in long term.
Companies commonly adopt product launches and expansion strategies to expand their footprint worldwide, meet the growing demand, and expand their product portfolio. The players operating in the global human papillomavirus (HPV) vaccine market implement the strategy of product innovation for changing customer demand worldwide, which also permits them to maintain their brand name globally.
By geography, the human papillomavirus (HPV) vaccine market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South & Central America). GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders are among the leading companies operating in the market.